Michinori Ogura

Japanese Red Cross Nagoya Daini Hospital — Japan

Medicine · Health Sciences

51h-index10.5kcitations335works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(204), Chronic Lymphocytic Leukemia Research(89), Viral-associated cancers and disorders(64), CAR-T cell therapy research(45), Monoclonal and Polyclonal Antibodies Research(38)

Publications333 total

Final results of JCOG0601 randomized trial of R-CHOP versus CHOP combined with dose-dense rituximab for diffuse large B-cell lymphoma
Japanese Journal of Clinical Oncology·2025
Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203
Hematological Oncology·2024· 2 citedOpen Access
Author response for "Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203"
2024
<scp>R‐CHOP</scp> treatment for patients with advanced follicular lymphoma: Over 15‐year follow‐up of <scp>JCOG0203</scp>
British Journal of Haematology·2023· 11 citedOpen Access
Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601
Blood·2023Open Access
Long‐term follow‐up after <scp>R‐High CHOP</scp>/<scp>CHASER</scp>/<scp>LEED</scp> with <scp>Auto‐PBSCT</scp> in untreated mantle cell lymphoma—Final analysis of <scp>JCOG0406</scp>
Cancer Science·2023· 1 citedOpen Access
Supplementary Methods from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Supplementary Tables 1 and 2 from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Data from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Supplementary Methods from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Data from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Supplementary Tables 1 and 2 from Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
2023Open Access
Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma
Blood·2022
A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan
Cancer Chemotherapy and Pharmacology·2022· 1 citedOpen Access
Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
Annals of Hematology·2022· 8 citedOpen Access
Supplementary Material for: Safety and Efficacy of Self-Expandable Metallic Stent Placement Using Low Radial Force Stent for Malignant Dysphagia after Radiotherapy
Figshare·2022Open Access
A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma
Journal of Clinical and Experimental Hematopathology·2022· 2 citedOpen Access
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study
Blood Advances·2021· 9 citedOpen Access
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study
Clinical Lymphoma Myeloma & Leukemia·2021· 13 citedOpen Access
MO12-5 Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
Annals of Oncology·2021
page 1 of 17Next →

Frequent Co-authors

Kensei Tobinai(22), Yoshitoyo Kagami(14), Naokuni Uike(11), Ritsuro Suzuki(11), Yasuo Morishima(11), Shigeo Nakamura(10), Kiyoshi Ando(9), Ryuzo Ueda(8), Masao Seto(8), Taizan Suchi(8), Yasushi Yatabe(7), Masafumi Taniwaki(7), Toshiki Uchida(7), Kunihiro Tsukasaki(6), Masaru Kojima(6), Hirofumi Taji(6), Kenichi Ishizawa(6), Yukio Kobayashi(6), Kuniaki Itoh(6), Kazuhito Yamamoto(5)